GALT
NASDAQ · Biotechnology
Galectin Therapeutics Inc
$3.93
+0.03 (+0.77%)
Open$3.86
Previous Close$3.90
Day High$3.99
Day Low$3.80
52W High$7.13
52W Low$2.03
Volume—
Avg Volume326.7K
Market Cap399.36M
P/E Ratio—
EPS$-0.43
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+229.8% upside
Current
$3.93
$3.93
Target
$12.96
$12.96
$9.51
$12.96 avg
$17.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 42.71M | 37.98M | 43.70M |
| Net Income | -4,071,906 | -4,331,190 | -4,441,576 |
| Profit Margin | -9.5% | -11.4% | -10.2% |
| EBITDA | -6,278,520 | -5,337,134 | -5,924,921 |
| Free Cash Flow | -4,174,488 | -3,744,064 | -5,531,991 |
| Rev Growth | +12.9% | +2.3% | +21.5% |
| Debt/Equity | 0.88 | 1.10 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |